**Research article: Early Prognostic Instrumental & Laboratory Markers in Post-MI**

Running tittle: Current Advances in Cardiopathologies Management

**Authors' list: Basheer Abdullah Marzoog[1,*], Averina Daria Romanovna[2]**

[1] National Research Mordovia State University. Address: Bolshevitskaya Street, 68, Saransk, Rep. Mordovia, Russia. Postal address: Russia, Mordovia republic, Saransk, Bolshevitskaya Street, 31, 430005.

[2] Sechenov First Moscow State Medical University. Address: Trubetskaya St., bld. 2, Moscow, 119991. ORCID: 0009-0004-9377-2241

[*]Corresponding author: Basheer Abdullah Marzoog, undergraduate medical school student at National Research Mordovia State University (marzug@mail.ru, +79969602820). Address: Bolshevitskaya Street, 68, Saransk, Rep. Mordovia, 430005. Postal address: Mordovia republic, Saransk, Bolshevitskaya Street, 31. ORCID: 0000-0001-5507-2413, Scopus ID: 57486338800

Competing interests: No competing interests regarding the publication.

All authors read and approved the final version of the manuscript

**Abstract**

**Background**: Post-myocardial infarction (MI) changes have been frequently reported in the literature and are associated with determining the prognosis.

**Aims**: To find a prognosis marker for the favorability of determination of the medium-term outcomes in patients with acute MI.

**Objectives**: MI victims' prognosis is poorly understood and required further elaboration.

**Materials and methods**: A single cross-sectional study involved 211 patients' medical history with acute MI have been evaluated retrospectively for 76 parameters for the period 2014-2019. The data has been collected from the Republic Rehabilitation Mordovian Hospital. Measurement units are used in the local laboratories has been used to describe the gotten values. The descriptive values are described in the mean average and standard deviation. For statistical analysis, descriptive statistics, t-test independent by groups and dependent by numerical variables for repeated analysis for the same patients, Pearson's correlation coefficient, ROC analysis, Stepwise Model Builder- logistic regression analysis, and for clarification purposes used diagrams and bar figures. For statistical analysis used the Statistica program.

**Results**: Descriptive statistics showed a proportion of men to female 7:3. The mean age of the MI victims was 61.50 years (Std.Dev. ± 10.6875) and the mean height of the sample was 171.00 cm (Std.Dev. ± 7.2007). The mean body weight of the sample is 83.62 kg (Std.Dev. ± 12.3526) and the body mass index (BMI) is 29.02 kg/m$^2$ (Std.Dev. ± 5.0791). The mean total hospitalization days is 14.79 (Std.Dev. ± 3.4125) days. The mean heart rate (HR) beat per minute (bpm) 79.03 (Std.Dev. ± 15.6370) and mean blood pressure 138.53/84.09 mmHg (Std.Dev. ± 28.6691/12.7971). On the complete blood count (CBC), the mean level of the hemoglobin (Hb) 136.332 g/l (Std.Dev. ± 15.2923), the mean level of the leukocytes (WBC) 8.768 /µl (Std.Dev. ± 2.7771), the mean level of the red blood cells (RBC) 4.559 /µl (Std.Dev. ± 0.5211), the mean level of the lymphocytes 24.469 % (Std.Dev. ± 9.0153), and the mean level of the thrombocytes 207.877 /µl (Std.Dev. ± 64.0350). The means erythrocytes segmentation rate (ESR) 18.990 mm/hr (Std.Dev. ± 12.1630).

**Conclusions**: The gender plays an essential role for the development of ischemic heart disease including MI. The cut age in which females develop MI ≥73 years old. Patients with concomitant diseases have a high diastolic blood pressure and right ventricle size enlargement. The observed early post MI complication include left ventricle aneurysm and reinfarction.

**Others**: A high calcium level is not a marker in hypertensive patients.

**Keywords**: Myocardial infarction, statistics, retrospective, IHD, Regeneration, Myocardiocyte, Angiogenesis

**Background**

Current statistics showed that cardiovascular events remain the predominant cause of mortality and morbidity in our era [1]. Many aspects of post-MI changes remain in the womb of development. Therefore, determination of the exact life expectancy for victims of MI still an obstacle [2–4]. Myocardial infarction ranks first in the frequency of causes of mortality. Myocardial infarction involves necrosis of the myocardiocytes and disturbance to the basic functions of the heart tissue including the automatism, conduction, and contraction functions. Transmural myocardial infarction involves necrosis of full wall thickness and is related to one of the classical types of myocardial infarction (MI1-5). MI-1 rupture of coronary atherosclerosis and further formation of thromboembolism, MI-2 spasm of the coronary artery, MI-3 sudden cardiac death, MI-4a after percutaneous coronary intervention (PCI), MI-4b after coronary artery stenting, MI-5 after coronary artery bypass graft (CABG) [5, 6]. Typical MI has a classical clinical presentation that includes a typical pain character and localization that does not respond to nitroglycerine and has more than 15 mints accompanied by shortness of breath.

The pathophysiology of myocardial infarction includes a mismatch between the demand and supply of heart tissue with the blood [7, 8]. Subsequently, cardiac cells start to suffer ischemia and is associated with sequalae, such as oxidative stress due to the deterioration of the mitochondrial bilayer membrane and cell membrane [3, 9, 18, 19, 10–17]. The lipid content of membranes plays an essential role in cardiac cells in terms of ischemia, and, at the same time, maintaining stability during ischemia has a protective effect against ischemia [20]. Therefore, lipid peroxidation is an important step in the pathogenesis of myocardial infarction. In addition, physiologically, cells suffering ischemia, upregulates autophagy in hope of rescuing the cell from ischemic damage by self-digestion of intracellular components such as impaired organelles. However, prolonged ischemia is usually already present in MI victims, but autophagy markers will be dramatically high in advancing the stage of ischemia. Using autophagy markers as a sign of myocardiocytes ischemia is possible in terms of short period ischemia and to follow up the stage of ischemia according to the level of autophagy markers in serum [10]. The selectivity of autophagy markers is the current challenge for scientists. However, to overcome this problem, a suggestion is to expose invitro myocardiocytes to ischemia and assess the particular markers of autophagy that are selective for

myocardiocytes. thereby, autophagy markers will be the earliest in the diagnosis of pre-MI and to avoid the necrosis of myocardiocytes.

One of the early laboratory signs of myocardial cell necrosis is elevation in the cardiac enzymes including the cardiac troponins, lactate dehydrogenase 1, and creatinine phosphokinase-MB fraction. Furthermore, an instrumental rapid diagnostic method for MI is electrocardiogram (ECG).

**Methods**

The study involved 211 patients with myocardial infarction for the period of the 2014-2019. Primary data collected from the Mordovian Republican Rehabilitation Hospital. The criteria for including the patient in the study is patients with MI who in less than 31 days asked for help in the rehabilitation hospital. Therefore, all these patients implanted into rehabilitation program for improving post MI prognosis and palliative care. All the missed data has been treated as an absent. Statically significant values have been described at $p<0.05$. The missing data in each variable are not included in the absolute and relative values of the study. The number of participants with missing data for each variable has been described in the frequency table as a supplementary file. Measurement units are used in the local laboratories. The study approved by the National Research Mordovia State University, Russia, from "Ethics Committee Requirement N8/2 from 30.06.2022".

For statistical analysis, descriptive statistics, t-test independent by groups and dependent by numerical variables for repeated analysis for the same patients, Pearson's correlation test, ROC analysis, Stepwise Model Builder- logistic regression analysis, and for clarification purposes used diagrams and bar figures. Not necessarily all the results of the mentioned statistical analysis exist in the paper because only the tests with statistically significant value have been described. For the statistical analysis used the StatSoft, Inc. (2014). STATISTICA (data analysis software system), version 12. www.statsoft.com.

**Results**

The descriptive statistics showed a proportion of male to female 7:3. The mean age of the MI victims was 61.50 years (Std.Dev. ± 10.6875) and the mean height of the sample, 171.00 cm (Std.Dev. ± 7.2007). The mean body weight of the sample is 83.62 kg (Std.Dev. ± 12.3526) and the body mass index (BMI) is 29.02 kg/m$^2$ (Std.Dev. ± 5.0791). The mean total hospitalization days is 14.79 (Std.Dev. ± 3.4125) days. Mean heart rate (HR) beat per minute (bpm) 79.03 (Std.Dev. ± 15.6370) and mean blood pressure 138.53/84.09 mmHg (Std.Dev. ± 28.6691/12.7971). On the complete blood count (CBC), the mean level of the hemoglobin (Hb) 136.332 g/l (Std.Dev. ± 15.2923), the mean level of the leukocytes (WBC) 8.768 /µl

(Std.Dev. ± 2.7771), the mean level of red blood cells (RBC) 4.559 /µl (Std.Dev. ± 0.5211), the mean level of lymphocytes 24.469 % (Std.Dev. ± 9.0153), and the mean level of the thrombocytes 207.877 /µl (Std.Dev. ± 64.0350). The mean segmentation rate (ESR) 18.990 mm / hour (Std.Dev. ± 12.1630).

In terms of biochemical analysis, the mean level of alanine transpeptidase (ALT) is 41.124 U/l (Std.Dev. ± 42.9736) and the mean level of the aspartate transpeptidase (AST) 58.786 U/l (Std.Dev. ± 71.1159). Furthermore, the mean level of creatinine 82.767 µmol/l (Std.Dev. ± 29.5238), the mean level of urea is 6.694 mmol/l (Std.Dev. ± 2.0727), and the mean level of venous glucose 6.997 mmol/l (Std.Dev. ± 2.9877). The mean level of the total bilirubin 16.204 mmol/l (Std.Dev. ± 6.4563).

Changes in lipid profile are observed, the mean total cholesterol level 5.278 mmol/l (Std.Dev. ± 1.3331), low density lipoprotein (LDL) 3.257 mmol/l (Std.Dev. ± 1.0924), and the triacylglycerol (TAG) 1.724 mmol/l (Std.Dev. ± 0.9118). Additionally, changes in the coagulogram results are also observed, the mean level of the activated thromboplastin time (aPTT) 27.820 s (Std.Dev. ± 8.0940), and the mean value of international normalization ratio (INR) 1.102 (Std.Dev. ± 0.3711).

Electrolytes changes are expressed in MI patients, mean sodium level in serum 142.241 mmol/l (Std.Dev. ± 4.8351), and the mean level of potassium 4.561 mmol/l (Std.Dev. ± 6.6401), and the mean calcium level 1.283 mmol/l (Std.Dev. ± 1.0612).

Specific cardiac marker changes are presented in the troponin I and creatinine phosphokinase-MB fraction and lactate dehydrogenase 1. The mean level of troponin-I 5.349 ng/l (Std.Dev. ± 8.6458) and the mean level of the creatinine phosphokinase-MB fraction (CPK-MB) 100.364 U/l (Std.Dev. ± 259.3624). Furthermore, the mean level of lactate dehydrogenase-1 (LDH-1) was 685.596 U/l (Std.Dev. ± 574.2033). The mean level of myoglobin 111.30 ng/ml (Std.Dev. ± 76.8340).

Changes in the instrumental findings including echocardiogram changes. The mean diameter of the aorta in the Valsalva sinus is 35.577 mm (Std.Dev. ± 4.3003). The mean ejection fraction (EF) 54.194 % (Std.Dev. ± 9.4554). The mean end diastolic volume (EDV) 138.749 ml (Std.Dev. ± 39.1890). Additionally, the mean end diastolic size of the left ventricle, left atrium, right ventricle, right atrium 52.872 mm, 40.295 mm, 26.935 mm, 36.062 mm (Std.Dev. ± 7.4707/5.1539/ 4.0704/ 4.4526), respectively.

In the general urine analysis, the mean level of urine protein 1.831 (Std.Dev. ± 11.8201) and the mean level of the urine WBC in the field of the vision 2.800 (Std.Dev. ± 7.8727). And the mean level of epithelial cells in vision 1.617 (Std.Dev. ± 2.4533).

In terms of pre-MI concomitant disease, arterial hypertension stands in the first place. (*Figure 1*)

The most frequently reported post-MI complication is heart failure and various types of arrythmia. In patients with pre-existing CHF, the degree or severity of heart failure has worsened and changed to a more advanced stage. (*Figure 2*)

Several factors attribute to the worsening of the post MI prognosis shown in table 1. The variability in these parameters are associated with the grouping factors.

Table 1: Results of the T-test to group the sample according to different principles to assess the potential role of each. Only statically significant parameters have been shown in the table.

| Variable | T-tests; Grouping: Gender<br>Group 1: F<br>Group 2: M | | | | |
|---|---|---|---|---|---|
| | Mean F | Mean M | t-value | df | p |
| Age | 65.26 | 59.73 | 3.72539 | 209 | 0.000251 |
| Height | 164.67 | 173.07 | -3.84356 | 35 | 0.000490 |
| BMI | 31.96 | 27.81 | 2.50249 | 36 | 0.017012 |
| SBP | 144.40 | 135.41 | 2.25373 | 205 | 0.025272 |
| Aorta dimeter at Valsalva sinus | 33.19 | 36.68 | -5.78550 | 200 | 0.000000 |
| EDV (ML) | 128.60 | 143.56 | -2.36302 | 169 | 0.019264 |
| EDS of RA (MM) | 35.06 | 36.53 | -2.17269 | 193 | 0.031022 |
| Hb (g/l) | 129.89 | 139.39 | -4.29775 | 200 | 0.000027 |
| RBC /L | 4.44 | 4.62 | -2.16953 | 163 | 0.031491 |
| Urine epithelial cells | 2.41 | 1.25 | 3.12240 | 191 | 0.002073 |
| Myoglobulin (ng/ml) | 199.90 | 67.00 | 19.18246 | 1 | 0.033158 |
| LDH 2 (U/l) | 409.91 | 713.16 | -2.47399 | 71 | 0.015754 |
| Glucose (mmol/l) | 7.79 | 6.63 | 2.53778 | 192 | 0.011950 |
| Variable | T-tests; Grouping: Concomitant disease<br>Group 1: Yes<br>Group 2: No | | | | |
| | Mean Yes | Mean No | t-value | df | p |
| DBP | 84.56 | 79.09 | 2.03247 | 203 | 0.043409 |

| | | | | | |
|---|---|---|---|---|---|
| EDS of RV (MM) | 27.15 | 24.93 | 2.34008 | 198 | 0.020276 |
| INR | 1.06 | 1.47 | -4.86557 | 177 | 0.000003 |
| Variable | T-tests; Grouping: DM<br>Group 1: No<br>Group 2: Yes | | | | |
| | Mean No | Mean Yes | t-value | df | p |
| Age | 60.55 | 64.96 | -2.5331 | 204 | 0.012057 |
| Aorta dimeter at Valsalva sinus | 35.87 | 34.39 | 2.0399 | 196 | 0.042697 |
| EDS of LV (MM) | 52.20 | 54.87 | -2.0736 | 181 | 0.039529 |
| Hb (g/l) | 137.75 | 131.91 | 2.2609 | 195 | 0.024871 |
| Myoglobulin (ng/ml) | 67.00 | 199.90 | -19.1825 | 1 | 0.033158 |
| TAG (mmol/l) | 1.62 | 2.14 | -3.3127 | 189 | 0.001107 |
| Glucose (mmol/l) | 6.17 | 9.90 | -8.3336 | 188 | 0.000000 |
| Variable | T-tests; Grouping: Hypertension<br>Group 1: Yes<br>Group 2: No | | | | |
| | Mean Yes | Mean No | t-value | df | p |
| Age | 62.24 | 58.32 | 2.06235 | 204 | 0.040442 |
| SBP | 140.73 | 128.33 | 2.50247 | 200 | 0.013134 |
| DBP | 85.15 | 80.14 | 2.25165 | 199 | 0.025437 |
| EDS of LA (MM) | 40.68 | 38.45 | 2.27065 | 195 | 0.024261 |
| LDH 1 (U/l) | 643.44 | 921.24 | -2.21515 | 140 | 0.028365 |
| INR | 1.05 | 1.35 | -4.21313 | 174 | 0.000040 |
| TAG (mmol/l) | 1.79 | 1.44 | 2.01466 | 189 | 0.045358 |
| Ca (mmol/l) | 1.20 | 1.68 | -2.18942 | 162 | 0.029997 |
| Variable | T-tests; Grouping: CKD<br>Group 1: No<br>Group 2: Yes | | | | |
| | Mean No | Mean Yes | t-value | df | p |
| EDS of LV (MM) | 52.49 | 57.50 | -2.16124 | 178 | 0.032013 |

| | | | | | |
|---|---|---|---|---|---|
| Troponin I (ng/ml) | 4.77 | 19.25 | -4.85863 | 172 | 0.000003 |
| CPK-MB 1(U/l) | 89.05 | 372.14 | -3.20560 | 171 | 0.001609 |
| Variable | T-tests; Grouping: COPD<br>Group 1: No<br>Group 2: Yes | | | | |
| | Mean No | Mean Yes | t-value | df | p |
| EDS of RV (MM) | 26.81 | 28.91 | -1.99714 | 195 | 0.047201 |
| leukocytes /L | 8.64 | 10.08 | -2.02454 | 193 | 0.044292 |
| Urine protein | 1.27 | 8.90 | -2.41397 | 191 | 0.016724 |
| LDH 1 (U/l) | 653.47 | 1047.86 | -2.47174 | 140 | 0.014645 |
| ALT (mmol/l) | 38.93 | 63.81 | -2.22692 | 192 | 0.027115 |
| Variable | T-tests; Grouping: Dyslipidemia<br>Group 1: No<br>Group 2: Yes | | | | |
| | Mean No | Mean Yes | t-value | df | p |
| Total cholesterol (mmol/l) | 5.21 | 5.92 | -2.45779 | 191 | 0.014871 |
| LDL (mmol/l) | 3.20 | 3.77 | -2.42518 | 187 | 0.016251 |
| Na (mmol/l) | 142.50 | 140.01 | 2.17050 | 174 | 0.031324 |
| Ca (mmol/l) | 1.34 | 0.81 | 1.99261 | 162 | 0.047984 |
| Variable | T-tests; Grouping: Varicose vein<br>Group 1: No<br>Group 2: Yes | | | | |
| | Mean No | Mean Yes | t-value | df | p |
| ESR (mm/hr.) | 18.28 | 33.40 | -2.86024 | 190 | 0.004707 |
| Fibrinogen (mg/dl) | 3439.63 | 4325.00 | -2.39330 | 162 | 0.017842 |
| Variable | T-tests; Grouping: Complications<br>Group 1: Yes<br>Group 2: No | | | | |
| | Mean Yes | Mean No | t-value | df | p |

| | | | | | |
|---|---|---|---|---|---|
| Total hospitalization days | 14.91 | 11.43 | 2.89231 | 207 | 0.004233 |
| EDS of RA (MM) | 35.91 | 40.40 | -2.25749 | 192 | 0.025103 |
| K (mmol/l) | 4.09 | 21.53 | -6.37437 | 182 | 0.000000 |
| Ca (mmol/l) | 1.20 | 4.07 | -6.66743 | 166 | 0.000000 |
| Variable | T-tests; Grouping: Arrythmia<br>Group 1: Yes<br>Group 2: No | | | | |
| | Mean Yes | Mean No | t-value | df | p |
| Total hospitalization days | 15.53 | 14.56 | 2.07859 | 205 | 0.038900 |
| Age | 63.89 | 60.46 | 2.23887 | 205 | 0.026239 |
| EF (%) | 50.85 | 55.50 | -3.32859 | 196 | 0.001043 |
| EDS of LA (MM) | 42.05 | 39.53 | 3.24848 | 196 | 0.001365 |
| EDS of RA (MM) | 37.88 | 35.24 | 3.92822 | 192 | 0.000119 |
| Troponin I (ng/ml) | 8.36 | 4.00 | 3.20317 | 176 | 0.001614 |
| CPK-MB 1(U/l) | 172.83 | 69.12 | 2.50073 | 178 | 0.013297 |
| LDH 1 (U/l) | 906.96 | 589.07 | 3.17184 | 143 | 0.001854 |
| ALT (mmol/l) | 54.25 | 35.44 | 2.86748 | 193 | 0.004597 |
| AST (mmol/l) | 78.37 | 48.51 | 2.81321 | 194 | 0.005410 |
| TAG (mmol/l) | 1.50 | 1.83 | -2.34537 | 191 | 0.020034 |
| Variable | T-tests; Grouping: Re-infarct MI<br>Group 1: Yes<br>Group 2: No | | | | |
| | Mean Yes | Mean No | t-value | df | p |
| Age | 64.07 | 60.75 | 2.08949 | 208 | 0.037879 |
| Variable | T-tests; Grouping: Aneurysm<br>Group 1: No<br>Group 2: Yes | | | | |
| | Mean No | Mean Yes | t-value | df | p |
| EF (%) | 55.18 | 43.59 | 5.13333 | 198 | 0.000001 |
| Urine epithelial cells | 1.44 | 3.63 | -3.51931 | 191 | 0.000541 |

| | | | | | |
|---|---|---|---|---|---|
| Troponin I (ng/ml) | 4.99 | 9.99 | -2.02501 | 178 | 0.044361 |
| Variable | T-tests; Grouping: Pericarditis<br>Group 1: No<br>Group 2: Yes | | | | |
| | Mean No | Mean Yes | t-value | df | p |
| EDS of LA (MM) | 40.19 | 45.50 | -2.05662 | 199 | 0.041028 |
| Variable | T-tests; Grouping: Pneumonitis<br>Group 1: No<br>Group 2: Yes | | | | |
| | Mean No | Mean Yes | t-value | df | p |
| Aorta dimeter at Valsalva sinus | 35.66 | 20.00 | 3.73889 | 199 | 0.000242 |
| leukocytes /L | 8.72 | 14.80 | -2.20307 | 197 | 0.028749 |
| ESR (mm/hr.) | 18.78 | 48.00 | -2.42454 | 194 | 0.016244 |
| Urine leukocytes | 2.72 | 22.00 | -2.46896 | 197 | 0.014402 |
| CPK-MB 1(U/l) | 94.87 | 1164.00 | -4.29558 | 178 | 0.000029 |
| Variable | T-tests; Grouping: D-dimer (ng/l)<br>Group 1: Increased<br>Group 2: Normal | | | | |
| | Mean Increased | Mean Normal | t-value | df | p |
| LDH 1 (U/l) | 353.88 | 808.50 | -2.28113 | 10 | 0.045698 |

In terms of correlation, several interesting correlations have been found including a proportional correlation between the HR and EF. (*Figure 3*) Further correlations are shown in (*Table 2*) and figures in the (*supplementary file 1*).

**Discussion**

The heart is a central organ in the regulation of hemodynamics with the help of the autonomic nervous system and the endocrine system. Disturbances in this complex is associated with development of clinical and subclinical manifestations. Several causes are related to the deterioration of heart function including and not limited to coronary vascular disease. Furthermore, additional agents have been seen to cause cardiomyopathy including the COVID-19 [13].

High normal blood pressure observed in MI victims as well as overweight is a landmark for the development of MI. The gender plays an essential role for the development of ischemic heart disease including MI. The cut age in which females develop MI ≥73 years old. High body weight in females is observed in compare to males which is not associated with dramatic increase in the risk of MI in females. The systolic blood pressure in males is higher and is associated with the early age of development of myocardial infarction in males. The diameter of the aorta in the Valsalva sinus is greater in males compared to the anatomical diameter in the aorta of females. Moreover, gender is crucial in determination of the level of the LDH which is higher in males.

Patients with concomitant diseases have a high diastolic blood pressure which is related to the heart failure and or the calcification of the elastic and musculoelastic blood vessels. Furthermore, patients with concomitant diseases have an increased right ventricle size. Suggesting that heart failure was usually right side of the hear (large circulation).

Concomitant diabetic mellites is observed in elderly patient with a small aortic diameter as well as left ventricular size. Furthermore, diabetic patients with a low Hb level and a high TAG level with dramatically high post-MI myoglobulin.

Hypertensive patients are usually with advanced age and is usually isolated systolic blood pressure is high. Additionally, post-MI hypertensive patients have a low $Ca+^{2}$, INR, LDH level, and high TAG and EDS of the left atrium. Indicates that a high calcium level is not a marker in hypertensive patients. In addition, hypertensive patients do not have a high coagulation time or LDH after MI in compare to the non-hypertensive. Additionally, hypertriglyceridemia and hypertrophy of the left atrium are features in hypertensive patients. Hypertriglyceridemia is not a unique feature for patients with hypertension, in some patients can be elevated LDL or both. Therefore, dyslipidemia is more typical in hypertensive patients.

CKD is a worsening factor for EDS of LV, Troponin I, and CPK-MB. In patients with advanced chronic kidney disease, hypertrophy of the left ventricle and dramatic persistent elevation in post-MI cardiac markers due to the impaired kidney detoxification function of the kidneys.

Interestingly, concomitant diseases such as COPD, associated with hypertrophy of the right ventricle and increase in the EDS of the RV. Moreover, COPD patients have a dramatically high levels of serum leukocytes, proteinuria, serum LDH, and serum ALT. suggesting that COPD are have a chronic inflammation and prolonged liver intoxication resulted in toxic

hepatitis. In terms of post-MI laboratory changes in COPD patients, the LDH level is extremely high in COPD patients.

MI patients have a high level of total cholesterol, LDL, and low Ca and Na levels. The hypothesis of dyslipidemia as an essential modified risk factor for the development of MI is supported.

MI varicosed patients have a mild chronic inflammation presented by the high ESR and fibrinogen. Hypercoagulation syndrome predominant in MI patients.

Post MI complications are associated with prolonged hospitalization days in the intensive care unit. Furthermore, complications are related to the low EDS of RA, hypokalemia, and hypocalcemia. Arrythmia is one of the most frequently reported complication in post MI. arrhythmic patients have a prolonged hospitalization in the ICU and elevated LA EDS, RA troponin I, CPK-MB, LDH, ALT, and AST. Arrythmia develops in later ages and is related with reduction in the EF.

Reinfarction is found to be reported in older age as a nonmodified risk factor. Early complications include left ventricle aneurysm that is seen with elevated urine epithelial cells and troponin I. Furthermore, aneurysm of the left ventricle is associated with dramatic reduction of the ejection fraction. Dressler syndrome includes pericarditis, pneumonitis, and pleuritis, which is typical of a late post-MI complication. According to the results of the data, the early post MI complication was pericarditis which was associated with the increase in the EDS of LA. Suggesting that pericarditis is associated with dilated left atrium. Additionally, an early pot MI complication is pneumonitis, which is seen in patients with a low aorta dimeter in the Valsalva sinus. Interestingly, MI complicated with pneumonitis is associated with higher plasma leukocytes, ESR, Urine leukocytes, and CPK-MB. This leads to additional inflammation of the pleura and to an increase in pro-inflammatory markers. Surprisingly, LDH is higher in normal D-dimer patients.

MI patients have a laboratory indicator of chronic inflammatory process presented by elevation of ESR level. High AST is a characteristic feature of patients with MI in acute stage. MI patients have a preserved EF heart failure (HFpEF).

A single study demonstrated that elevated troponin T is possible in patients with neuromuscular diseases [21]. Therefore, a separate elevation of cardiac troponin T is not sufficient for the diagnosis of MI.

**Conclusions**

The gender plays an essential role for the development of ischemic heart disease including MI [2, 22, 23]. The cut age in which females develop MI ≥73 years old. A proportional

correlation between HR and EF. Patients with concomitant diseases have a high diastolic blood pressure which is related to the heart failure and or the calcification of the elastic and musculoelastic blood vessels. Patients with concomitant diseases have a larger right ventricle size. Suggesting that heart failure was usually right side of the hear (large circulation).

In terms of post-MI laboratory changes, in COPD patients, the LDH level is extremely high. Patients with concomitant hypertension after MI have a low $Ca+^{2}$, INR, LDH level and high TAG and EDS of the left atrium. Dyslipidemia is more typical in hypertensive patients. Additionally, hypertriglyceridemia and hypertrophy of the left atrium are features in hypertensive patients. Concomitant CKD is a worsening factor for EDS of LV, troponin I, and CPK-MB levels. Concomitant diabetic patients have low Hb level and high TAG level with a dramatically high post MI myoglobulin.

Early complications include left ventricle aneurysm that is seen with elevated urine epithelial cells and troponin I. Reinfarction is found to be reported in older age as a nonmodified risk factor. MI patients have a laboratory indicator of chronic inflammatory process presented by elevation of ESR level. High AST is a characteristic feature of patients with MI in acute stage. Early post MI patients have a preserved EF heart failure (HFpEF). Interestingly, MI complicated with pneumonitis is associated with higher plasma leukocytes, ESR, Urine leukocytes, and CPK-MB. Post-MI remodeling is a classic change supported by majority of the studies [24].

**List of abbreviations**

CHF; chronic heart failure, DM; Diabetes mellitus, CKD; Chronic kidney disease, COPD; Chronic obstructive pulmonary disease, MI; myocardial infarction, HR; heart rate, ESR; erythrocytes sedimentation rate, RBC; red blood cells

**Declarations**

1. Ethics approval and consent to participate: The study approved by the National Research Mordovia State University, Russia, from “Ethics Committee Requirement N8/2 from 30.06.2022”.
2. Consent for publication: Written informed consent was obtained from the participants for publication of study results and any accompanying images.
3. Availability of data and materials: applicable on reasonable request.
4. Competing interests: The authors declare that they have no competing interests regarding publication.
5. Funding’s: Not applicable (This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors)

6. Authors' contributions: MB is the writer, researcher, collected and analyzed data, and revised the manuscript. **Daria Romanovna Averina** inserted the data from the patient's history into excel table. All authors have read and approved the manuscript.
7. Acknowledgments: not applicable
8. Authors' information: Basheer Abdullah Marzoog, National Research Mordovia State University (marzug@mail.ru, +79969602820). Address: Bolshevitskaya St., 68, Saransk, Rep. Mordovia, 430005. ORCID: 0000-0001-5507-2413. **Daria Romanovna Averina**, Sechenov First Moscow State Medical University. Address: Trubetskaya St., bld. 2, Moscow, 119991. ORCID: 0009-0004-9377-2241
9. The paper has not been submitted elsewhere

**References**

[1] Tsao, C. W.; Aday, A. W.; Almarzooq, Z. I.; Anderson, C. A. M.; Arora, P.; Avery, C. L.; Baker-Smith, C. M.; Beaton, A. Z.; Boehme, A. K.; Buxton, A. E.; et al. Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association. *Circulation*, **2023**. https://doi.org/10.1161/CIR.0000000000001123.

[2] Abdullah Marzoog, B. Adaptive and Compensatory Mechanisms of the Cardiovascular System and Disease Risk Factors in Young Males and Females. *New Emirates Med. J.*, **2022**, *04*. https://doi.org/10.2174/04666221128110145.

[3] Marzoog, B. A. Tree of Life: Endothelial Cell in Norm and Disease, the Good Guy Is a Partner in Crime! *Anat. Cell Biol.*, **2023**. https://doi.org/10.5115/acb.22.190.

[4] Marzoog, B. A.; Alexandrovich, K. O.; Nikolaevich, T. M.; Vladimirovich, K. S. Post-Coronary Artery Bypass Graft Complications; Potential Causes and Risk Factors. *New Emirates Med. J.*, **2023**, *04*. https://doi.org/10.2174/0250688204666230410084313.

[5] Thygesen, K.; Alpert, J. S.; Jaffe, A. S.; Chaitman, B. R.; Bax, J. J.; Morrow, D. A.; White, H. D. Fourth Universal Definition of Myocardial Infarction (2018). *J Am Coll Cardiol*, **2018**, *72* (18), 2231–2264. https://doi.org/10.1016/j.jacc.2018.08.1038.

[6] Neumann, J. T.; Weimann, J.; Sörensen, N. A.; Hartikainen, T. S.; Haller, P. M.; Lehmacher, J.; Brocks, C.; Tenhaeff, S.; Karakas, M.; Renné, T.; et al. A Biomarker Model to Distinguish Types of Myocardial Infarction and Injury. *J. Am. Coll. Cardiol.*, **2021**, *78* (8), 781–790. https://doi.org/10.1016/J.JACC.2021.06.027.

[7] Boyette, L. C.; Manna, B. Physiology, Myocardial Oxygen Demand. *StatPearls*, **2022**.

[8] Vásquez-Trincado, C.; García-Carvajal, I.; Pennanen, C.; Parra, V.; Hill, J. A.; Rothermel, B. A.; Lavandero, S. Mitochondrial Dynamics, Mitophagy and

Cardiovascular Disease. *J. Physiol.*, **2016**, *594* (3), 509–525. https://doi.org/10.1113/JP271301.

[9] Marzoog, B. A.; Alexandrovich, K. O.; Nikolaevich, T. M.; Vladimirovich, K. S. Post-Coronary Artery Bypass Graft Complications; Potential Causes and Risk Factors. *medRxiv*, **2023**, 2022.12.29.22284005. https://doi.org/10.1101/2022.12.29.22284005.

[10] Marzoog, B. A.; Vlasova, T. I. Myocardiocyte Autophagy in the Context of Myocardiocytes Regeneration: A Potential Novel Therapeutic Strategy. *Egypt. J. Med. Hum. Genet.*, **2022**, *23* (1), 41. https://doi.org/10.1186/s43042-022-00250-8.

[11] Marzoog, B. A.; Vlasova, T. I. The Metabolic Syndrome Puzzles; Possible Pathogenesis and Management. *Curr. Diabetes Rev.*, **2022**, *18*. https://doi.org/10.2174/1573399818666220429100411.

[12] Marzoog, B. Lipid Behavior in Metabolic Syndrome Pathophysiology. *Curr. Diabetes Rev.*, **2021**, *18* (6). https://doi.org/10.2174/1573399817666210915101321.

[13] Marzoog, B. A. Pathophysiology of Cardiac Cell Injury in Post-Covid-19 Syndrome. *New Emirates Med. J.*, **2023**, *4*. https://doi.org/10.2174/0250688204666230428120808.

[14] Marzoog, B. A. Endothelial Cell Autophagy in the Context of Disease Development. *Anat. Cell Biol.*, **2023**, *56* (1), 16–24. https://doi.org/10.5115/acb.22.098.

[15] Marzoog, B. A. Transcription Factors - the Essence of Heart Regeneration: A Potential Novel Therapeutic Strategy. *Curr. Mol. Med.*, **2023**, *23* (3), 232–238. https://doi.org/10.2174/1566524022666220216123650.

[16] Marzoog, B. A. Systemic and Local Hypothermia in the Context of Cell Regeneration. *Cryo Letters*, **2022**, *43* (2), 66–73. https://doi.org/10.54680/fr22210110112.

[17] Marzoog, B. A.; Bloshkina, N. I.; Gromova, V. S.; Gorshinina, E. I. Myocardial Infarction; Early Prognostic Instrumental & Laboratory Markers: Single Cross-Sectional Analysis. *medRxiv*, **2023**.

[18] Marzoog, B. A. Autophagy Behaviour in Post-Myocardial Infarction Injury. *Cardiovasc. Hematol. Disord. Targets*, **2023**.

[19] Marzoog, B. A. Recent Advances in Molecular Biology of Metabolic Syndrome Pathophysiology: Endothelial Dysfunction as a Potential Therapeutic Target. *J. Diabetes Metab. Disord.*, **2022**, *21* (2), 1903–1911. https://doi.org/10.1007/s40200-022-01088-y.

[20] Marzoog, B. A.; Vlasova, T. I. Membrane Lipids under Norm and Pathology. *Eur. J. Clin. Exp. Med.*, **2021**, *19* (1), 59–75. https://doi.org/10.15584/ejcem.2021.1.9.

[21] Rittoo, D.; Jones, A.; Lecky, B.; Neithercut, D. Elevation of Cardiac Troponin T, but Not Cardiac Troponin I, in Patients with Neuromuscular Diseases: Implications for the Diagnosis of Myocardial Infarction. *J. Am. Coll. Cardiol.*, **2014**, *63* (22), 2411–2420. https://doi.org/10.1016/J.JACC.2014.03.027.

[22] Ahmad, Y. Al; Ali, M. T.; Ahmad, Y. Al; Ali, M. T. Non-ST Elevation Myocardial Infarction: Diagnosis and Management. *Myocard. Infarct.*, **2019**. https://doi.org/10.5772/INTECHOPEN.76241.

[23] JS, B.; L, E.; D, G.; M, R.; CB, G.; PW, A.; RJ, S.; HD, W.; F, V. de W.; EJ, T.; et al. Sex Differences in Mortality Following Acute Coronary Syndromes. *J Am Med Assoc*, *302*, 874–882.

[24] Frantz, S.; Hundertmark, M. J.; Schulz-Menger, J.; Bengel, F. M.; Bauersachs, J. Left Ventricular Remodelling Post-Myocardial Infarction: Pathophysiology, Imaging, and Novel Therapies. *Eur. Heart J.*, **2022**, *43* (27), 2549–2561. https://doi.org/10.1093/eurheartj/ehac223.

**Figures legend**




Figure 1: Most frequently concomitant diseases reported in MI victims. Descending arranges for the concomitant diseases by frequency of occurrence. Abbreviations: CHF; chronic heart

failure, DM; diabetes mellitus, COPD; chronic obstructive lung disease, CKD; chronic kidney disease.




Figure 2: Most frequently reported complications post PCI and MI in MI victims. Descending arranges for the complications by frequency of occurrence. Abbreviations: CHF; chronic heart failure, MI; myocardial infarction.




Figure 3: Proportional correlation between the heart rate and the ejection fraction.

**Table legend**

Table 2: T-test results for grouping of the sample by different principles to evaluate the potential role of each. Only statically significant parameters are shown in the table.

Table 2: Correlation between the numerical parameters of the sample.